Glatopa is a generic version of COPAXONE® (glatiramer acetate injection) to treat relapsing-forms of multiple sclerosis1
Glatopa has been approved by the FDA as a fully substitutable version of COPAXONE®. Now, you can get therapeutically equivalent treatment with less financial burden.
The medicine you expect, the support you deserve1,2
Glatopa is an FDA-approved generic that can be substituted for COPAXONE®.
- Contains the same active ingredient
- Offers the same dosage therapeutic effect
- Is administered the same way (under the skin)
- Backed by GlatopaCare patient support services
Whether you are switching to Glatopa from COPAXONE®, or just getting started with glatiramer acetate, you can be sure you're receiving the same FDA-approved medicine found in COPAXONE®.1
Quality backed by knowledge
- Glatopa meets rigorous FDA quality standards for production6
- Glatopa is made in the United States7
- Brought to you by Sandoz, one of the leading generic pharmaceutical companies in the world
Glatopa® (glatiramer acetate injection) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Important Safety Information
Do not take Glatopa® if you are allergic to glatiramer acetate, mannitol, or any of the ingredients in Glatopa.
Some patients report a short-term reaction right after or within minutes after injecting glatiramer acetate. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain, fast heartbeat, anxiety, and trouble breathing. These symptoms generally appear within seconds to minutes of an injection, last about 15 minutes, and do not require specific treatment. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care. If symptoms become severe, call the emergency phone number in your area. Call your healthcare provider right away if you develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, or severe pain at the injection site. If any of the above occurs, do not give yourself any more injections until your healthcare provider tells you to begin again.
Chest pain may occur either as part of the immediate post-injection reaction or on its own. This pain should only last a few minutes. You may experience more than one such episode, usually beginning at least one month after starting treatment. Tell your healthcare provider if you experience chest pain that lasts for a long time or feels very intense.
A permanent indentation under the skin (lipoatrophy) or, rarely, necrosis at the injection site may occur, due to local destruction of fat tissue. Be sure to follow proper injection technique and inform your healthcare provider of any skin changes.
Liver problems, including liver failure, can occur with Glatopa. Call your healthcare provider right away if you have symptoms, such as: nausea, loss of appetite, tiredness, dark colored urine and pale stools, yellowing of your skin or the white part of your eye, bleeding more easily than normal, confusion, sleepiness.
The most common side effects in studies of glatiramer acetate injection are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These are not all of the possible side effects of glatiramer acetate. For a complete list, ask your healthcare provider or pharmacist. Tell your healthcare provider about any side effects you have while taking Glatopa.
To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information for Glatopa.
1. U.S. Department of Health & Human Services. Approved Drug Products With Therapeutic Equivalence Evaluations: 41st Edition. Washington, DC: US Department of Health and Human Services; 2021. 2. Glatopa Prescribing Information. Sandoz Inc. July 2020. 3. GlatopaCare provides free individualized support to MS patients, families, and caregivers. Glatopa website. https://www.glatopa.com/glatopacare/what-is-glatopacare/. Accessed June 29, 2021. 4. Here for Support. Copaxone website. https://www.copaxone.com/shared-solutions. Accessed June 29, 2021. 5. Copaxone Prescribing Information. Teva Pharmaceuticals. April 2022. 6. FDA approves first generic Copaxone to treat multiple sclerosis [press release]. US Food and Drug Administration; April 16, 2015. https://wayback.archive-it.org/7993/20171102214315/ https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm443143.htm. Accessed March 26, 2020. 7. Bell C, Anderson J, Ganguly T, et al. J Pharm Pract. 2018;31(5):481-488.